patritumab
daiichi sankyo
['patritumab', 'mbc']
her3+ mbc. encouraging early data with patritumab-dxd across all subtypes. 6% of patients developed ild. #asco22 
Hematology/Oncology fellow @EinsteinMed @MontefioreNYC via @slusom and @USJLiban. Interested in EBM & clinical reasoning. Views are my own.